Skip to main content
Top
Published in: Virology Journal 1/2021

Open Access 01-12-2021 | SARS-CoV-2 | Research

The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients

Authors: Pooneh Rahimi, Rahil Tarharoudi, Alireza Rahimpour, Jalal Mosayebi Amroabadi, Iraj Ahmadi, Enayat Anvari, Seyed Davar Siadat, Mohammadreza Aghasadeghi, Abolfazl Fateh

Published in: Virology Journal | Issue 1/2021

Login to get access

Abstract

Background

The recent pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has elevated several clinical and scientific questions. These include how host genetic factors influence the pathogenesis and disease susceptibility. Therefore, the aim of this study was to evaluate the impact of interferon lambda 3 and 4 (IFNL3/4) gene polymorphisms and clinical parameters on the resistance and susceptibility to coronavirus disease 2019 (COVID-19) infection.

Methods

A total of 750 SARS-CoV-2 positive patients (375 survivors and 375 nonsurvivors) were included in this study. All single-nucleotide polymorphisms (SNPs) on IFNL3 (rs12979860, rs8099917, and rs12980275) and IFNL4 rs368234815 were genotyped by the polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) method.

Results

In this study, a higher viral load (low PCR Ct value) was shown in nonsurvivor patients. In survivor patients, the frequency of the favorable genotypes of IFNL3/4 SNPs (rs12979860 CC, rs12980275 AA, rs8099917 TT, and rs368234815 TT/TT) was significantly higher than in nonsurvivor patients. Multivariate logistic regression analysis has shown that a higher low-density lipoprotein (LDL), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and PCR Ct value, and lower 25-hydroxyvitamin D, and also IFNL3 rs12979860 TT, IFNL3 rs8099917 GG, IFNL3 rs12980275 GG, and IFNL4 rs368234815 ∆G/∆G genotypes were associated with the severity of COVID-19 infection.

Conclusions

The results of this study proved that the severity of COVID-19 infection was associated with clinical parameters and unfavorable genotypes of IFNL3/IFNL4 SNPs. Further studies in different parts of the world are needed to show the relationship between severity of COVID-19 infection and host genetic factors.
Literature
1.
go back to reference Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020;250(4):271–8.CrossRef Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020;250(4):271–8.CrossRef
2.
go back to reference Amodio E, Pipitone RM, Grimaudo S, Immordino P, Maida CM, Prestileo T, et al. SARS-CoV-2 viral load, IFNλ polymorphisms and the course of COVID-19: an observational study. J Clin Med. 2020;9(10):3315.CrossRef Amodio E, Pipitone RM, Grimaudo S, Immordino P, Maida CM, Prestileo T, et al. SARS-CoV-2 viral load, IFNλ polymorphisms and the course of COVID-19: an observational study. J Clin Med. 2020;9(10):3315.CrossRef
3.
go back to reference Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H, Dutta S. Emergence of novel coronavirus and COVID-19: whether to stay or die out? Crit Rev Microbiol. 2020;46(2):182–93.CrossRef Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H, Dutta S. Emergence of novel coronavirus and COVID-19: whether to stay or die out? Crit Rev Microbiol. 2020;46(2):182–93.CrossRef
4.
go back to reference Casanova J-L, Su HC, COVID Human Genetic Effort. Effort CHG A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell. 2020;181(6):1194–9.CrossRef Casanova J-L, Su HC, COVID Human Genetic Effort. Effort CHG A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell. 2020;181(6):1194–9.CrossRef
5.
go back to reference Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23.CrossRef Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23.CrossRef
6.
go back to reference van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324(7):663–73.CrossRef van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324(7):663–73.CrossRef
7.
go back to reference Sakhaee F, Ghazanfari M, Vaziri F, Jamnani FR, Davari M, Gharibzadeh S, et al. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infect Genet Evol. 2017;54:330–7.CrossRef Sakhaee F, Ghazanfari M, Vaziri F, Jamnani FR, Davari M, Gharibzadeh S, et al. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infect Genet Evol. 2017;54:330–7.CrossRef
8.
go back to reference Sedighimehr P, Irani S, Sakhaee F, Vaziri F, Aghasadeghi M, Sadat SM, et al. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol. 2017;162(1):181–9.CrossRef Sedighimehr P, Irani S, Sakhaee F, Vaziri F, Aghasadeghi M, Sadat SM, et al. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol. 2017;162(1):181–9.CrossRef
9.
go back to reference Asnavandi M, Zargar M, Vaziri F, Jamnani FR, Gharibzadeh S, Fateh A, et al. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun. 2017;18(3):144–51.CrossRef Asnavandi M, Zargar M, Vaziri F, Jamnani FR, Gharibzadeh S, Fateh A, et al. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun. 2017;18(3):144–51.CrossRef
10.
go back to reference Rugwizangoga B, Andersson ME, Kabayiza JC, Nilsson MS, Ármannsdóttir B, Aurelius J, et al. IFNL4 genotypes predict clearance of RNA viruses in Rwandan children with upper respiratory tract infections. Front Cell Infect Microbiol. 2019;9:340.CrossRef Rugwizangoga B, Andersson ME, Kabayiza JC, Nilsson MS, Ármannsdóttir B, Aurelius J, et al. IFNL4 genotypes predict clearance of RNA viruses in Rwandan children with upper respiratory tract infections. Front Cell Infect Microbiol. 2019;9:340.CrossRef
11.
go back to reference Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006;80(9):4501–9.CrossRef Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006;80(9):4501–9.CrossRef
12.
go back to reference Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-λ contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008;4(9):e1000151.CrossRef Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-λ contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008;4(9):e1000151.CrossRef
13.
go back to reference Zhou JH, Wang YN, Chang QY, Ma P, Hu Y, Cao X. Type III interferons in viral infection and antiviral immunity. Cell Physiol Biochem. 2018;51(1):173–85.CrossRef Zhou JH, Wang YN, Chang QY, Ma P, Hu Y, Cao X. Type III interferons in viral infection and antiviral immunity. Cell Physiol Biochem. 2018;51(1):173–85.CrossRef
14.
go back to reference Monavari SH, Fateh R, Vaziri F, Rahimi Jamnani F, Anvari E, Sadeghi F, et al. A comparative study of various methods for detection of IL28B rs12979860 in chronic hepatitis C. Scand J Clin Lab Invest. 2017;77(4):247–52.CrossRef Monavari SH, Fateh R, Vaziri F, Rahimi Jamnani F, Anvari E, Sadeghi F, et al. A comparative study of various methods for detection of IL28B rs12979860 in chronic hepatitis C. Scand J Clin Lab Invest. 2017;77(4):247–52.CrossRef
15.
go back to reference Pouryasin M, Sharafi H, Behnava B, Alavian SM, Keshvari M, Pouryasin A. A simple PCR-RFLP method for genotyping of IFNL4 rs368234815 polymorphism in patients with chronic hepatitis C. Lab Med. 2017;48(1):51–6.CrossRef Pouryasin M, Sharafi H, Behnava B, Alavian SM, Keshvari M, Pouryasin A. A simple PCR-RFLP method for genotyping of IFNL4 rs368234815 polymorphism in patients with chronic hepatitis C. Lab Med. 2017;48(1):51–6.CrossRef
16.
go back to reference Chu CM, Poon LL, Cheng VC, Chan KS, Hung IF, Wong MM, et al. Initial viral load and the outcomes of SARS. CMAJ. 2004;171(11):1349–52.CrossRef Chu CM, Poon LL, Cheng VC, Chan KS, Hung IF, Wong MM, et al. Initial viral load and the outcomes of SARS. CMAJ. 2004;171(11):1349–52.CrossRef
17.
go back to reference Yu X, Sun S, Shi Y, Wang H, Zhao R, Sheng J. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. Crit Care. 2020;24(1):170.CrossRef Yu X, Sun S, Shi Y, Wang H, Zhao R, Sheng J. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. Crit Care. 2020;24(1):170.CrossRef
18.
go back to reference Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.CrossRef Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.CrossRef
19.
go back to reference Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, Giannico OV, et al. Gender differences in patients with COVID-19: a narrative review. Monaldi Arch Chest Dis. 2020;90(2). Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, Giannico OV, et al. Gender differences in patients with COVID-19: a narrative review. Monaldi Arch Chest Dis. 2020;90(2).
20.
go back to reference Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep. 2020;10(1):20191.CrossRef Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep. 2020;10(1):20191.CrossRef
21.
go back to reference Weir EK, Thenappan T, Bhargava M, Chen Y. Does vitamin D deficiency increase the severity of COVID-19? Clin Med (Lond). 2020;20(4):e107–8.CrossRef Weir EK, Thenappan T, Bhargava M, Chen Y. Does vitamin D deficiency increase the severity of COVID-19? Clin Med (Lond). 2020;20(4):e107–8.CrossRef
22.
go back to reference Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function. Nutrients. 2013;5(7):2502–21.CrossRef Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function. Nutrients. 2013;5(7):2502–21.CrossRef
23.
go back to reference Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583.CrossRef Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583.CrossRef
24.
go back to reference Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep. 2017;16(5):7432–8.CrossRef Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep. 2017;16(5):7432–8.CrossRef
25.
go back to reference Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–8.CrossRef Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–8.CrossRef
26.
go back to reference Wang H, Yuan Z, Pavel MA, Jablonski SM, Jablonski J, Hobson R, et al. The role of high cholesterol in age-related COVID19 lethality. bioRxiv [Preprint]. 2021 June 28:2020.05.09.086249. Wang H, Yuan Z, Pavel MA, Jablonski SM, Jablonski J, Hobson R, et al. The role of high cholesterol in age-related COVID19 lethality. bioRxiv [Preprint]. 2021 June 28:2020.05.09.086249.
27.
go back to reference Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;130(5):2620–9.CrossRef Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;130(5):2620–9.CrossRef
28.
go back to reference Hemann EA, Gale M Jr, Savan R. Interferon lambda genetics and biology in regulation of viral control. Front Immunol. 2017;8:1707.CrossRef Hemann EA, Gale M Jr, Savan R. Interferon lambda genetics and biology in regulation of viral control. Front Immunol. 2017;8:1707.CrossRef
29.
go back to reference Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.CrossRef Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.CrossRef
30.
go back to reference Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.CrossRef Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.CrossRef
31.
go back to reference Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R, et al. COVID-19 and emerging viral infections: the case for interferon lambda. J Exp Med. 2020;217(5):e20200653.CrossRef Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R, et al. COVID-19 and emerging viral infections: the case for interferon lambda. J Exp Med. 2020;217(5):e20200653.CrossRef
Metadata
Title
The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients
Authors
Pooneh Rahimi
Rahil Tarharoudi
Alireza Rahimpour
Jalal Mosayebi Amroabadi
Iraj Ahmadi
Enayat Anvari
Seyed Davar Siadat
Mohammadreza Aghasadeghi
Abolfazl Fateh
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2021
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-021-01692-z

Other articles of this Issue 1/2021

Virology Journal 1/2021 Go to the issue